TREM2 and Alzheimer disease: Our studies provide further support for the direction of therapeutic modulation of TREM2, because an AD-protective PLCG2 variant has been shown to be mildly hypermorphic, indicating that increased PLCγ2 activity is beneficial for disease23,25.